Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: J Immunol. 2008 Jul 1;181(1):309–319. doi: 10.4049/jimmunol.181.1.309

Figure 1.

Figure 1

AHR in mice after systemic sensitization and airway challenge with OVA (2ip3N protocol). (a-d) Lung resistance (RL) and dynamic compliance (Cdyn) as percent changes from saline controls in relation to increasing doses of aerosolized MCh. Treatments: none (NT), intra-peritoneal sensitization and airway challenge (2ip3N), 2ip3N plus hamster IgG i.v., 2ip3N plus anti Vγ4 mAb UC3 i.v., 2ip3N plus purified Vγ4+ cells from 2ip3N-treated donors (wt or CD8α−/−) i.v. (a) Normal C57BL/6 mice after 2ip3N or 2ip3N plus depletion of Vγ4+ cells with mAb UC3 (* non-treated compared with 2ip3N, # 2ip3N compared with 2ip3N plus UC3); (b) B6.CD8α−/− mice after 2ip3N plus depletion of Vγ4+ cells with mAb UC3 (* non-treated compared with 2ip3N); (c) B6.TCR-Vγ4/6−/− mice after 2ip3N or 2ip3N plus Vγ4+ cells from B6.TCR-β−/−(CD8αwt) donors (* non-treated compared with 2ip3N; there was no significant difference between non-treated and 2ip3N plus WT Vγ4 cells) ; (d) B6.TCR-Vγ4/6−/− mice after 2ip3N or 2ip3N plus Vγ4+ cells from B6.CD8α−/− donors (there was no significant difference between 2ip3N and 2ip3N plus CD8−/− Vγ4 cells at any dose of MCh).